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Abstract 
The objective of the current work was to design an injectable, sustained 
release formulation of a combination of anticancer drugs, carboplatin 
and paclitaxel, for localized delivery. In this combination formulation, 
carboplatin was encapsulated into poly(L-lactide) (PLA) microspheres 
and paclitaxel was dissolved in thermosensitive biodegradable gel of 
PLGA-PEG-PLGA (poly (DL-lactide-co-glycolide- polyethylene 
glycol- poly (DL-lactide-co-glycolide)); no external solvent like 
cremophorEL was used in the formulation, further, these carboplatin 
microspheres were dispersed in the gel containing paclitaxel to achieve 
a single delivery system. The combined formulation was assessed for 
various parameters for sustained release of both the drugs. Release 
profiles of carboplatin from PLA microspheres; paclitaxel from 
hydrogel alone and in combination with carboplatin and carboplatin 
microspheres dispersed in paclitaxel loaded gel were studied. In vitro 
release of both the drugs from PLGA-PEG-PLGA hydrogel showed 
that carboplatin was released with 40-50% burst release and paclitaxel 
was released in biphasic manner for 50-60 days. Initial burst of 
carboplatin was controlled by incorporating it in PLA microspheres 
which were then dispersed in paclitaxel loaded hydrogel and the new 
formulation did not exhibit any burst release of the drug. Release 
pattern of combination formulations revealed that the two drugs were 
co-eluting from a single delivery system and the rate of release of each 
of the individual drugs was significantly affected. 
Thus, a novel injectable combination formulation for sustained and 
simultaneous delivery of carboplatin and paclitaxel was developed 
which provided sustained release of each of the drugs and could be 
further explored in tumor models. 
Keywords: Thermosensitive hydrogels, Microspheres, controlled 
release, combination chemotherapy. 
Introduction 
Combination chemotherapy is today being 
explored as one of the most attractive approaches 
to ensure total cell kill and complete remission in 
various cancerous diseases. Skipper and Schabel 
first described the importance of combination 
therapy on the basis of log kill hypothesis [1]. 
Combination of paclitaxel and platinum 
analogues (cisplatin and carboplatin) is already 
employed in clinical practice and this is a FDA 
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approved combination for the treatment of 
different types of cancers; viz. advanced ovarian 
cancer and lung cancer.  
 
Carboplatin is second generation platinum analog 
and acts as an alkylating agent. It is a cell cycle-
non specific agent having antiproliferative action. 
It is having molecular weight of approximately 
371.29 and solubility of 14 mg/ml. It is mainly 
used in treatment of ovarian cancer, and also in 
other types of cancers like lung, head, neck, 
endometrial cancers. More than 30% of the 
patients taking carboplatin experience side effects 
like low blood counts, thrombocytopenia, hair 
loss, peripheral neuropathy, diarrhea, general 
weakness etc. [2]. Paclitaxel is a water insoluble 
drug (aqueous solubility 4 µg/ml) and belongs to 
BCS class IV. It is soluble in organic solvents 
like alcohols, DMSO, chlorinated solvents. Its 
molecular weight is 853.9. Paclitaxel is having 
anti-proliferative, antimetastatic and anti-invasive 
actions [3]. It is mainly used in the treatment of 
ovarian, breast and non small cell lung cancer. 
Most serious side effect of paclitaxel is bone 
marrow depression especially neutropenia. 
Considering the individual efficacies of these two 
drugs in the treatment of cancer, carboplatin with 
paclitaxel have been combined based upon- 
 
i) Carboplatin and paclitaxel show promising 
single agent activities in metastatic breast 
cancer, and efficacy in various other cancers 
due to their complementary mechanisms of 
action [4].  
ii) Existence of inverse relationship between 
carboplatin and paclitaxel; as observed in 
resistant cell models where resistance to one 
led to sensitivity to the other [5].  
iii) When paclitaxel/carboplatin are used in 
combination; paclitaxel appears to have 
more platelet sparing action that reduces 
thrombocytopenia induced by administration 
of carboplatin alone [6].  
 
Considering the potential of this combination of 
anticancer drugs, it is of wide clinical utility, 
whereby conventional procedure for 
administration of paclitaxel and carboplatin 
combination involves 3 h infusion of paclitaxel 
followed by 30 min infusion of carboplatin or 
vice versa. Time required for reaching Cmax for 
carboplatin (Cmax 37 µg/ml) and paclitaxel (Cmax 
4.265 µg/ml) is 1 h and 3 h after infusion 
respectively [7, 8]. This cycle is repeated 3-4 
times after every 3 weeks.  This procedure is not 
patient complaint and is also associated with 
certain delivery and toxicity problems of each of 
the molecules due to systemic administration. 
Conventionally, paclitaxel is administrated as 
taxol® which is a marketed formulation of the 
drug containing cremophorEL to enhance its 
solubility (aqueous solubility of paclitaxel is 
4µg/ml) [9]. The use of cremophorEL is 
associated with serious side effects, particularly 
life threatening hypersensitivity reactions [10].  
 
In order to obviate the problems associated with 
systemic delivery of anticancer agents, localized 
delivery at the tumor site appears to be an 
attractive approach because this maximizes the 
therapeutic effect and minimizes the adverse 
effects. Polymeric controlled drug delivery 
systems particularly in situ depot forming 
systems have recently gained enormous interest 
to accomplish this task and triblock co-polymer, 
PLGA–PEG–PLGA is one such thermosensitive 
polymer explored widely. This system has been 
proved useful for delivery of single agents 
particularly for hydrophobic molecules [11-15]. 
Considering hydrophilic molecules, such as 
carboplatin are expected to exhibit burst release 
from this system. In order to overcome this 
problem, incorporation of hydrophilic drug into 
particulate carrier followed by dispersion into the 
gel may circumvent burst release along with 
prolonging the duration of release. Among 
particulate carriers, microparticles have certain 
advantages, such as easy method of preparation, 
scalability, high entrapment efficiency etc. 
Microparticles of biodegradable polymers like 
PLA are widely used because of its extensive 
safety profile and non toxicity [16]. 
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To the best of our knowledge, no attempt has 
been made to design a controlled release 
formulation of paclitaxel and carboplatin which 
could release both the drugs in simultaneous and 
sustained manner. In this study, we developed a 
combination formulation of these two drugs in in 
situ depot forming system PLGA-PEG-PLGA, 
where carboplatin microspheres (CP MS) were 
dispersed in biodegradable copolymer gel of 
PLGA-PEG-PLGA containing paclitaxel. This 
system is injectable and could be injected into the 
tumor directly. This would help in maintaining 
high locoregional concentrations of both the 
drugs, also eliminating the systemic adverse 
effects caused by these two potent molecules. 
However, designing such a formulation was a 
challenging task owing to the opposite 
physicochemical nature of the two drugs; 
paclitaxel being highly hydrophobic and 
carboplatin being highly hydrophilic. Further, the 
focus of the paper was to understand the release 
behavior of these two opposite nature drugs 
releasing simultaneously from a single delivery 
system and to optimize the system so as to obtain 
sustained release of both the drugs. 
 
Materials and methods 
Materials 
dl-Lactide and glycolide dimers were purchased 
from Purac and were used without further 
purification. Polyethylene glycol (MW 1000 Da; 
PEG1000) and stannous 2-ethylhexanoate were 
procured from Sigma Aldrich (Germany) and 
were used as received.  Paclitaxel was obtained as 
a gift from Prof. Avi Domb, Hebrew University 
of Jerusalem, Israel and carboplatin was 
generously gifted by Getwell Life Sciences (New 
Delhi, India). CremophorEL was purchased from 
Sigma Aldrich (Germany). All other chemicals 
used were of analytical grade. 
 
Synthesis and Characterization of PLA 
PLA polymer was synthesized by ring opening 
polymerization of dl-lactide using stannous-2-
ethylhexanoate as catalyst [17]. Synthesized 
polymer was characterized by GPC using 
Shimadzu LC-10AD HPLC and Shimadzu RID 
6A refractive index detector to know the weight 
average molecular weight (Mw), number average 
molecular weight (Mn) and polydispersity. 
 
Preparation and characterization of 
microspheres 
Preparation of microspheres 
Microspheres were prepared by acetonitrile/light 
mineral oil emulsion and solvent evaporation 
method. Carboplatin (10 mg) was dispersed in 
acetonitrile (1 ml) and sonicated with probe 
sonicator for 10 min to reduce the particle size. 
PLA (90 mg) solution in acetonitrile (1 ml) was 
added to the above dispersion. This internal phase 
(carboplatin + PLA + acetonitrile) was added to 
the external phase i.e. 40 ml of light liquid 
paraffin oil containing 1% w/w of surfactant 
(Span 80), while stirring at 500 rpm. The solvent 
(acetonitrile) was allowed to evaporate for 4 h. 
The particles obtained were washed in hexane 
and dried under vacuum. 
 
Size and surface morphology 
Size analysis of microspheres was performed by 
optical microscopy (Meiji Technology TC5500), 
images were captured by infinity camera and size 
was measured using “i solution” software 
(Version 7.2, iMTechnology). Surface 
morphology of microspheres was studied by 
Scanning Electron Microscopy (S-3400N, Hitachi 
Japan).  
 
Entrapment efficiency 
Weighed amount of microspheres (5 mg) were 
dissolved in methylene chloride followed by 
addition of water (5 ml) to this solution. This 
solution was vortexed using cyclomixer for 3 min 
to extract out the carboplatin into water. The drug 
content was then analyzed using  HPLC 
analytical method [18]. 
 
In vitro release study of carboplatin loaded 
microspheres 
Microspheres (~10 mg) were taken in dialysis 
bag (10000 M.W. cut off). This dialysis bag was 
transferred to a vial containing 5 ml of phosphate 
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buffer (pH 6.8; 100 mM) and placed in reciprocal 
shaking water bath maintained at 37ºC. An 
aliquot (1 ml) of the release medium was 
withdrawn at preset time points and volume 
withdrawn was replaced with fresh release 
medium. Drug content in samples was analyzed 
by HPLC.  
 
The release data was evaluated by model 
dependent analysis using the generic equations 
that mathematically translates the dissolution 
curve into a function of some parameter related to 
the pharmaceutical dosage form. There are 
several models where the amount of the drug (Q) 
is quantitatively interpreted as a function of test 
time (t) (Equation 1). Some of the commonly 
used analytical definitions of the Q (t) function 
are Zero-order, First-order, Higuchian and 
Hixson-Crowell’s models. 
                                            …Eq. 1 )(tfQ =
In vitro release data was fitted into these models 
and regression analysis was carried out. The 
measure for selecting the most suitable model 
was based on best goodness-of-fit. 
Synthesis and characterization of triblock 
copolymers 
Triblock copolymers (PLGA-PEG-PLGA) were 
synthesized following the method reported by 
Zentner et al. (15). In brief, ring opening 
polymerization was employed to bulk polymerize 
dl-lactide (LA) and glycolide (GA) using PEG as 
an initiator and stannous-2-ethyl hexanoate as 
catalyst. The copolymers were designated as 
PLGA-PEG-PLGA (x/y) where x/y is the ratio of 
lactide to glycolide. Molecular weight and 
molecular weight distribution were determined by 
GPC. Mn and lactide to glycolide ratios (LA/GA) 
were determined from 1H NMR. Test tube 
inverting method was used to determine gelation 
temperature of aqueous solutions (0.5 g) of 
polymers (25% w/w). 
 
Development of formulations  
Details of the formulations and their respective 
nomenclature have been enlisted in table 1. 
 
 
Table 1. Details of formulations and their respective nomenclature. 
Formulation Description Copolymer Abbreviations used 
Formulation 1 Carboplatin alone in gel LA/GA 3/1 -- 
Formulation 2 Paclitaxel alone in gel LA/GA 3/1 -- 
Formulation 3 Carboplatin and Paclitaxel combination in 
gel 
LA/GA 3/1 -- 
Formulation 4 Carboplatin alone in gel LA/GA 8/1 -- 
Formulation 5 Paclitaxel alone in gel LA/GA 8/1 -- 
Formulation 6 Carboplatin and Paclitaxel combination in 
gel 
LA/GA 8/1 -- 
Formulation 7 Carboplatin microspheres in gel LA/GA 3/1 CP MS in gel 
Formulation 8 Carboplatin microspheres in gel LA/GA 8/1 CP MS in gel 
Formulation 9 Carboplatin microspheres in paclitaxel 
loaded gel 
LA/GA 3/1 CP MS in paclitaxel 
containing gel 
Formulation 10 Carboplatin microspheres in paclitaxel 
loaded gel 
LA/GA 8/1 CP MS in paclitaxel 
containing gel 
* PLGA-PEG-PLGA of two different LA/GA ratios 3/1 and 8/1 were studied.  
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Formulation 1-6 (Carboplatin and/or 
paclitaxel in PLGA-PEG-PLGA): Copolymer 
was first dissolved in acetone followed by 
addition of the drug/s. Acetone was then 
evaporated under vacuum using Buchi rotavapor 
to form a drug-polymer matrix which was 
dissolved in purified water to obtain 25 % w/w of 
copolymer concentration.  
 
Formulation 7-8 (Carboplatin microspheres 
dispersed in PLGA-PEG-PLGA): Gel was 
prepared by dissolving 25 % w/w of copolymer 
in purified water. Microspheres equivalent to 1 
mg of carboplatin were then dispersed in the gel 
at low temperature (< 5°C).  
 
Formulation 9-10 (Carboplatin microspheres 
dispersed in PLGA-PEG-PLGA containing 
paclitaxel): Copolymer and paclitaxel were 
dissolved in acetone separately and the two 
solutions were then mixed. Acetone was 
evaporated under vacuum to form paclitaxel-
polymer matrix which was then dissolved in 
purified water to obtain 25 % w/w copolymer 
concentration. 
 
Microspheres equivalent to 1 mg of carboplatin 
were dispersed uniformly in gel containing 
paclitaxel.  
 
In vitro release studies  
For in vitro release studies, two different release 
media were employed to maintain sink 
conditions- phosphate buffer (pH 6.8; 100mM) 
was used for carboplatin alone formulations 
while phosphate buffer (pH 6.8; 100mM) with 
10% w/v cremophorEL was selected as release 
media for paclitaxel containing formulations due 
to its limited solubility in phosphate buffer.  
 
Formulation (~1 g) was taken in a vial and kept at 
37°C to equilibrate for 10 min to form gel. After 
10 min, 2 ml of release medium was added and 
sampling was done at regular time intervals 
wherein whole of the release media was 
withdrawn and replaced with the fresh media. 
The amount of drugs in the release samples was 
determined by a simultaneous HPLC method 
developed and validated in lab [18], and the 
release data was evaluated by model dependent 
analysis as mentioned above in section 2.3.4. 
 
Statistics 
The data obtained was analyzed by Student’s t-
test at all points using SPSS statistics (version 
17.0) software and a significance level of p < 
0.05 was denoted significant in all cases. 
 
Results and discussion 
Microspheres 
Synthesis and characterization of PLA 
PLA synthesized was white in color appearance, 
solid in nature, and yield obtained was more than 
80%. PLA was synthesized by ROP and 
characterized by GPC. Mw and Mn were found to 
be 55.06 kDa and 49.88 kDa respectively and 
polydispersity index was 1.1.  
 
Preparation and characterization of microspheres 
Carboplatin is a hydrophilic drug and is expected 
to show burst release from the gel matrix. To 
avoid the burst release, drug was first formulated 
in microspheres of hydrophobic polymer (i.e. 
PLA) by emulsion solvent evaporation method. 
Particle size analysis results suggested that 
carboplatin microspheres had a mean particle size 
of 28.22 ± 6.20 µm and SEM images of the 
microspheres showed that these were spherical 
and had smooth surfaces (Fig. 1). Microspheres 
were prepared at two different drug loadings 10% 
and 20% w/w and the corresponding entrapment 
efficiencies obtained were 85.6% and 62% 
respectively. A decrease in entrapment efficiency 
was observed as theoretical drug loading was 
increased. This might be due to the decrease in 
polymer concentration with corresponding 
increase in drug loading, resulting in formation of 
droplets with less viscous polymeric phase at a 
fixed internal phase ratio. This caused increase in 
escape of drug from the microspheres. Thus, 
increase in theoretical drug loading shows 
decrease in entrapment efficiency. 
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Figure 1. Carboplatin microspheres (CP MS) a) SEM image b) particle size distribution. 
 
 
Figure 2. In vitro release profile of carboplatin from CP MS (carboplatin loaded PLA microspheres). 
 
Carboplatin release from PLA microspheres 
showed a release for 8 h (Fig. 2) and followed 
Higuchian kinetics (table 3), thus, it is concluded 
that drug release from microspheres mainly 
followed diffusion dependent kinetics; this along 
with hydrophilic nature of the drug (aqueous 
solubility of 10-14 mg/ml) might be the reason 
for shorter duration of drug release. However, a 
more sustained release of carboplatin was desired 
for the intended application and to meet this end; 
these carboplatin microspheres were dispersed 
into PLGA-PEG-PLGA gel, which would 
provide an additional barrier for the drug to 
diffuse out of microspheres to reach the external 
environment. 
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Thermosensitive gel PLGA-PEG-PLGA 
Synthesis and characterization of triblock 
copolymers 
The copolymers with a predetermined molecular 
weight and LA to GA (3/1 and 8/1) ratios were 
synthesized. These copolymers were golden 
yellow in color and sticky in nature. Table 2 
shows the data obtained from 1H NMR and GPC. 
The feed ratios vs. practical ratios of LA/GA 
were also calculated by 1HNMR and results have 
been summarized in table 2. All these values 
were on expected lines and indicated the quality 
of the synthesized polymer. It has been reported 
that in order to exhibit the thermogelling 
properties, the overall molecular weight of these 
triblock copolymers should lie in the range of 
2000-4990 Da [13]. Results as obtained by both 
NMR and GPC indicated that all the copolymers 
were in the desired molecular weight range. 
Table 2 also shows the lower gelation 
temperature (Tlower) and upper gelation 
temperature (Tupper) for the copolymer solutions 
(25% w/v).  
 
 
Table 2. Characterization of the copolymers. 
 
Table 3. Model-fitting of the in vitro release profiles of carboplatin from different formulations. 
GPC NMR Sol-gel transition temperature (°C) 
Triblock 
copolymer 
(PLGA-PEG-
PLGA) 
Yield 
(%) Mna Mwb Mw/Mnc Mna LA/GAe 
% 
PEG 
Tlowerf Tupperg
Copolymer 1 
(LA/GA 3/1) 82.4 3534 4584 1.29 3126 2.98:1 31.97 16 50 
Copolymer 2 
(LA/GA 8/1) 81.4 3860 4840 1.25 2946 7.86:1 33.94 14 65 
a Number average molecular weight  
b Weight average molecular weight  
c Polydispersity  
e Molar ratio of lactic acid to glycolic acid (LA/GA)  
f Lower transition temperature from sol to gel 
g Upper transition temperature from gel to precipitate 
   Carboplatin 
  CP MS Formulation  1 
Formulation
 3 
Formulation
 4 
Formulation
 6 
Formulation
 7 
Formulation 
 8 
Formulation
 9 
Formulation 
10 
Intercept 30.2 77.48 61.439 61.099 65.806 28.7 25.4 31 26.48 
Slope 8.895 4.439 9.0629 8.0773 2.9817 11.55 9.466 12.28 9.79 Zero order 
R2 0.816 0.4131 0.7765 0.7029 0.7351 0.763 0.675 0.744 0.677 
Intercept 1.422 1.2876 1.5814 1.5929 1.5306 1.406 1.128 1.433 1.1.230 
Slope 0.086 -0.1291 -0.1768 -0.1753 -0.047 0.114 0.130 0.114 0.131 First order 
R2 0.579 0.6229 0.9021 0.9227 0.8185 0.617 0.40 0.612 0.353 
Intercept 14.28 70.718 55.677 51.488 62.853 16.46 12.91 19.04 14.65 
Slope 28.78 13.182 19.948 21.561 8.0133 31.48 28.54 33.06 29.09 Higuchi model 
R2 0.964 0.6544 0.9362 0.8996 0.8947 0.922 0.865 0.916 0.869 
Intercept 3.034 4.2485 3.9386 3.9203 4.0349 2.983 2.706 3.050 1.938 
Slope 0.228 0.0807 0.1735 0.1567 0.0579 0.302 0.296 0.309 0.378 
Hixon-
Crowell 
model R2 0.667 0.3816 0.741 0.6311 0.7089 0.676 0.522 0.664 0.716 
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Figure 3. In vitro release of carboplatin from formulation 1, 4, 7 and 8. Each point represents the mean ± SD; n= 3. 
Significant difference (p< 0.05) was observed at all time points denoted with an asterisk mark (*) (between 
formulation 1 and 4) and hash mark (#) (between formulation 7 and 8). 
Note: Formulations 1 and 4 contain carboplatin alone in copolymer 3/1 (LA/GA 3/1) and copolymer 8/1 (LA/GA 
8/1) respectively. Formulations 7 and 8 contain carboplatin loaded microspheres in copolymer 3/1 (LA/GA 3/1) and 
copolymer 8/1 (LA/GA 8/1) respectively. 
 
In vitro release 
It was a difficult task to design a matrix which 
would provide a sustained release for a 
combination of two opposite natured drugs like 
paclitaxel and carboplatin where one is 
hydrophobic and the other is hydrophilic in 
nature, respectively. To design such a delivery 
system, PLA microspheres were dispersed in 
thermosensitive in situ gelling system. In order to 
completely understand the release behavior of the 
two opposite nature drugs in combined 
formulation, selected formulations (as given in 
table 1) were designed and evaluated extensively 
for their drug release behavior. 
 
It is well known that drug release from the 
hydrogels occurs by two principal mechanisms: 
(i) drug diffusion from the hydrogel during the 
initial release phase and (ii) release of drug by the 
erosion of the hydrogel matrix during the later 
phase. In this case, two drug molecules showed 
characteristically different release profiles from 
the copolymer gels. Carboplatin showed an initial 
burst release and a shorter duration of release 
(formulations 1 and 4) (Fig. 3) whereas paclitaxel 
exhibited a completely different release profile 
with no burst effect and a very prolonged 
duration of release (formulation 2 and 5) (Fig. 5). 
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Figure 4. In vitro release study of carboplatin from formulation 7 and CP MS. Each point represents the mean ± SD; n= 3. 
Significant difference was observed at all the time points between CP MS and formulation 7. 
Note: Formulations 7 contains carboplatin microspheres in copolymer 3/1 (LA/GA 3/1) and CP MS contain carboplatin 
microspheres only. 
 
 
Figure 5. In vitro release study of paclitaxel from formulations 2 and 5. Each point represents the mean ± SD; n= 3. Significant 
difference (p< 0.05) was observed at all time points denoted with an asterisk mark (*). 
Note: Formulations 2 and 5 contain paclitaxel in copolymer 3/1 (LA/GA 3/1) and copolymer 8/1 (LA/GA 8/1) respectively. 
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Release profiles of formulations containing 
carboplatin alone 
Formulation 1 vs. 4:  In vitro release profile of 
carboplatin alone from copolymer gels showed 
three phases; an initial burst release phase, a 
sequential high release phase and a plateau region 
where very small amount of drug release was 
seen (Fig. 3). In this case, burst effect was more 
likely due to syneresis in the polymer. At 37°C, 
the gel contracted due to packing and aggregation 
of the micelles. This resulted in decrease in the 
system’s volume and expulsion of water. During 
this process, a substantial fraction of the 
dissolved drug came out with water leading to 
burst phenomenon. This was in agreement with 
reported results wherein, this push out effect was 
observed with drugs present in the hydrophilic 
domain of the gel (drug soluble in water) (19). 
PLGA-PEG-PLGA consists of hydrophobic 
PLGA domains and hydrophilic PEG domains; 
where carboplatin tends to get partitioned into the 
hydrophilic PEG domain because of its 
hydrophilic nature. Continuous release of 
carboplatin in second phase resulted from 
diffusion through hydrophilic channels of the 
hydrogel matrix. In this diffusion-predominant 
release phase, strength of hydrogel also created 
an impact upon the release behavior. A 
significant difference was observed in the release 
profiles from copolymer gels with LA to GA 
ratio 8/1 as compared to 3/1 at most of the time 
points. As strength of the gel increased (increase 
in LA/GA ratio from 3/1 to 8/1), a sustained 
release with the decrease in initial burst effect 
(from 55% to 40%) and absence of plateau phase 
was observed.  
 
Formulation 7 vs 8 :  When carboplatin was 
dispersed directly in the gel (formulation 1 & 4), 
a substantial fraction of the drug was expelled out 
of the system as burst release. In order to prevent 
this burst release, carboplatin microspheres were 
dispersed in gel (formulation 7 and 8). In vitro 
release profile of these formulations showed no 
burst release while a prolonged release of 6 and 7 
days was observed with 78.62 % and 71.83 % 
being released in first 3 days from formulation 7 
and 8, respectively. It was then followed by 
plateau phase where lesser amount of drug was 
released continuously (Fig. 3). No significant 
difference was observed in release profiles with 
copolymers having different LA/GA ratios. This 
is understood, as in this case carboplatin is 
entrapped in the PLA microspheres and is not 
present in PEG domains of the gel, thus the 
release is not affected by the contraction and 
hence the strength of the gel did not show any 
influence on the initial release.  
 
Formulation 7 vs plain carboplatin 
microspheres:  Release study of carboplatin 
from microspheres dispersed in gel (formulation 
7) showed drug release up to 6 days which is 
significantly longer than 8 h release of 
carboplatin as shown by PLA microspheres (Fig. 
4). This might be due to the fact that gel structure 
provided an additional barrier for diffusion of the 
drug from microspheres into the release media. 
Carboplatin, after diffusing out from 
microspheres, gets located in PEG domains of 
copolymer thus giving a significantly longer 
release. 
 
Summarizing release behavior of carboplatin 
from all these formulations, it is concluded that 
due to its hydrophilic nature, it gets located in to 
PEG domains of the copolymer and show faster 
and shorter duration of release. Copolymers with 
higher LA/GA ratio showed reduced burst effect. 
In order to prevent this burst release, CP MS 
were dispersed in gel, where absence of burst 
release was seen since drug is not present in 
soluble form but as solid reservoir in PLA 
microspheres. CP MS in gel significantly 
sustained the release of carboplatin as compared 
to the plain carboplatin microspheres due to 
additional barrier provided by the gel, after 
diffusing out from the microspheres. Thus, 
microspheres dispersed in gel provided a better 
delivery system for obtaining sustained release of 
such a hydrophilic molecule without any burst 
release. 
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Release profiles of formulations containing 
paclitaxel alone 
Formulation 2 vs 5: No burst release of 
paclitaxel was observed from these formulations; 
however, a biphasic release profile was seen (Fig. 
5). Paclitaxel is a hydrophobic drug and thus it is 
expected that it will remain in hydrophobic 
PLGA domains of the gel. Due to this reason, it is 
not affected by the contraction of the gel and 
corresponding syneresis; resulting in the absence 
of burst release from the formulations. Initial 
phase of paclitaxel release is diffusion-controlled 
while degradation predominates in the later 
phase, hence, no significant difference was 
observed during the initial phase of release from 
the copolymer gels having different LA/GA 
ratios at individual time points, though, % release 
was higher in formulation 2 having lower LA/GA 
ratio, but later phase exhibited a significant 
difference where both diffusion and rate of 
hydrogel erosion were decreased with increasing 
LA/GA ratio (12, 15). 
 
Release profiles of formulations containing 
combination of drugs 
Release profile of carboplatin from combination 
formulations (formulation 3 and 6) reveals a 
significantly more controlled release during 
initial phase as compared to carboplatin alone 
formulations (formulation 1 and 4) (Fig. 6). 
Initial phase of carboplatin release is primarily 
due contraction of the gel in the aqueous media 
and syneresis, resulting in expulsion of the drug 
out of the system. Simultaneous presence of 
paclitaxel in the system along with carboplatin 
makes the gels more hydrophobic (due to its 
hydrophobic nature) and hence stronger. The 
increase in the hydrophobicity of the system 
decreases the contraction of the gel structure 
along with decrease in the affinity of the release 
media towards the gel thereby controlling the 
release of the hydrophilic molecule in the initial 
phase. Change in the hydrophobicity of the 
system has a strong influence upon the nature of 
release as has also been observed in the release 
patterns obtained from copolymer gels containing 
different LA/GA ratios (formulation 1 vs. 4); as 
the lactide content increased (LA/GA ratio 
increased from 3:1 to 8:1, i.e. increasing the 
hydrophobicity) a significant decrease in the 
carboplatin release was observed (Fig. 6). 
 
 
 
Figure 6. In vitro release study of carboplatin from formulations 1, 3, 4 and 6. Each point represents the mean ± SD; n= 3. 
Significant difference (p< 0.05) was observed at all time points between formulation 1 and 3 and 4 and 6. 
Note: Formulations 1 and 4 contains carboplatin alone in copolymer respectively, formulations 3 and 6 contain carboplatin and 
paclitaxel combination in copolymer gels 3/1 and 8/1 respectively. 
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Figure 7. In vitro release study of carboplatin from formulations 7, 8, 9, and 10. Each point represents the mean ± SD; n= 3.  
Note: Formulations 7 and 8 contain carboplatin microspheres (CP MS) dispersed in copolymer 3/1 and 8/1 respectively. 
Formulations 9 and 10 contain CP MS dispersed in paclitaxel loaded copolymer 3/1 and 8/1 respectively. 
 
 
Figure 8. In vitro release study of paclitaxel from formulations 2 and 5 vs. 3 and 6. Each point represents the mean ± SD; n= 3.  
Note: Formulations 2 and 5 contain paclitaxel alone in copolymer 3/1 (LA/GA 3/1) and copolymer 8/1 (LA/GA 8/1) respectively. 
Formulations 3 and 6 contain paclitaxel in combination formulations along with carboplatin in copolymer 3/1 and 8/1 
respectively. 
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Carboplatin release from MS in gel formulations 
(formulations 9 vs. 10, 7 vs. 9 and 8 vs. 10, Fig. 
7) did not show a significant difference in the 
release profiles. This could be attributed to the 
fact that the initial phase of release in this case 
unlike previous formulations; is not dependent 
upon the contraction of the gels. Moreover, here, 
the drug is not surface located rather it is 
encapsulated into the PLA microspheres that 
controlled the release during the initial phase. 
Thus, the change in hydrophobicity of the 
polymer (either by changing the LA/GA ratio or 
by the simultaneous presence of hydrophobic 
molecule like paclitaxel) bears no effect on the 
release pattern of carboplatin.  
 
In case of release behavior shown by paclitaxel, 
the combination formulations (formulations 3 and 
6) were found to exhibit a significantly faster 
release as compared to paclitaxel alone 
formulations (formulations 2 and 5) (Fig. 8). In 
this case, co-eluting drug carboplatin is 
hydrophilic in nature and releasing at a faster 
rate, thus, creating channels filled with release 
media. These channels would have provided 
additional passage for the paclitaxel molecules to 
diffuse out thereby causing faster release. Not 
much difference in release was observed at day 1, 
as paclitaxel is located in the hydrophobic PLGA 
domains and is not affected by the contraction of 
the gels. However, after one day, significantly 
faster release was observed which is due to the 
creation of additional channels by carboplatin 
during its release.  
 
Formulation (3 and 6) vs (9 and 10):   Both the 
drugs when formulated in PLGA-PEG-PLGA 
gel, (formulations 3 and 6), showed high burst 
release of carboplatin (~55 %) (Fig. 6). To 
overcome the burst release, CP MS in gel 
formulation was designed, no burst effect was 
observed and increased duration of release was 
obtained (Fig. 7). This is due to the fact that 
carboplatin is present as solid reservoir in PLA 
microspheres (formulations 9 and 10) and drug 
has to cross the additional barrier of gel after 
diffusing out of the microspheres. In case of 
paclitaxel, no significant difference in release was 
observed as in both the cases paclitaxel was 
formulated in the copolymer gel only. 
 
Table 4.  Model-fitting of the in vitro release profiles of paclitaxel from different formulations. 
 
  Paclitaxel 
  Formulation 2 Formulation 3 Formulation 5 Formulation 6 Formulation 9 Formulation 10
Intercept 13.581 17.571 13.972 15.808 18.30 17.83 
Slope 1.5275 1.693 1.2749 1.6528 1.508 1.352 Zero order 
R2 0.9288 0.8726 0.8636 0.876 0.912 0.917 
        
Intercept 1.9643 1.9386 1.9452 1.9473 1.147 1.173 
Slope -0.0135 -0.0154 -0.0096 -0.0148 0.020 0.018 First order 
R2 0.9902 0.9849 0.9365 0.9744 0.590 0.606 
        
Intercept -0.4008 3.5329 0.8682 1.5707 3.172 3.679 
Slope 11.367 12.011 9.8574 12.01 11.66 9.557 
Higuchi 
model 
R2 0.9915 0.9943 0.9639 0.9931 0.995 0.985 
        
Intercept 2.2789 2.4198 2.2848 2.3046 2.454 2.440 
Slope 0.0521 0.0572 0.0466 0.0557 0.048 0.043 
Hixon-
Crowell 
models R2 0.662 0.5803 0.6337 0.6115 0.663 0.550 
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Model dependent analysis of release data showed 
release of the drugs from above mentioned 
formulations, mainly followed Higuchian model 
(Tables 3 and 4). 
 
Conclusions 
An injectable sustained release formulation for 
localized delivery containing combination of 
paclitaxel and carboplatin was developed by 
dispersing carboplatin loaded PLA microspheres 
in paclitaxel loaded thermosensitive gel. Shorter 
duration of carboplatin release (up to 6-7 days) 
along with a continuous and prolonged release of 
paclitaxel (up to 55- 60 days) was obtained which  
is in simulation with conventional therapy of this 
combination, in which carboplatin blood levels 
get diminished much earlier (25 h) than paclitaxel 
blood levels (50-55 h). Co-eluting drug molecules 
have significant effect on the release behavior of 
each of the individual drugs i.e. presence of 
hydrophobic molecules in the system, decrease 
and slow down the release rate of hydrophilic 
drug, while, presence of hydrophilic drug in the 
system, causes an increase in the release of 
hydrophobic drug. Thus, this system holds 
potential for simultaneous delivery of these 
anticancer agents which might yield better 
therapeutic efficacy and decreased side effects 
and resistance in tumor cells. 
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